Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of TAK-925 in Healthy Volunteers and Narcolepsy Type 1
NCT03332784Phase 1Completed
- Sponsor
- Takeda
- Start
- Nov 2017
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of danavorexton in narcolepsy type 1 (NT1) (9 arms), sponsored by Takeda. Primary endpoints: Number of Participants Reporting One or More Treatment-emergent Adverse Events, Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration and 1 more. Started Nov 2017; status: completed.
02
Drugs
danavorexton
03
Conditions
narcolepsy type 1 (NT1)
Beyond the preview
Go deeper on NCT03332784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03332784.